594 related articles for article (PubMed ID: 31670078)
1. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
[TBL] [Abstract][Full Text] [Related]
2. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
[TBL] [Abstract][Full Text] [Related]
3. CSF1R- and SHP2-Inhibitor-Loaded Nanoparticles Enhance Cytotoxic Activity and Phagocytosis in Tumor-Associated Macrophages.
Ramesh A; Kumar S; Nandi D; Kulkarni A
Adv Mater; 2019 Dec; 31(51):e1904364. PubMed ID: 31659802
[TBL] [Abstract][Full Text] [Related]
4. Supramolecular Nanotherapeutics for Macrophage Immunotherapy.
Ramesh A; Brouillard A; Kulkarni A
ACS Appl Bio Mater; 2021 Jun; 4(6):4653-4666. PubMed ID: 35007018
[TBL] [Abstract][Full Text] [Related]
5. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.
Wen J; Wang S; Guo R; Liu D
Eur J Med Chem; 2023 Jan; 245(Pt 1):114884. PubMed ID: 36335744
[TBL] [Abstract][Full Text] [Related]
6. Polymersomes-Mediated Delivery of CSF1R Inhibitor to Tumor Associated Macrophages Promotes M2 to M1-Like Macrophage Repolarization.
Rodriguez-Perdigon M; Jimaja S; Haeni L; Bruns N; Rothen-Rutishauser B; Rüegg C
Macromol Biosci; 2022 Aug; 22(8):e2200168. PubMed ID: 35624036
[TBL] [Abstract][Full Text] [Related]
7. Supramolecular nanotherapeutics enable metabolic reprogramming of tumor-associated macrophages to inhibit tumor growth.
Ramesh A; Malik V; Brouillard A; Kulkarni A
J Biomed Mater Res A; 2022 Aug; 110(8):1448-1459. PubMed ID: 35388955
[TBL] [Abstract][Full Text] [Related]
8. Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.
Czako B; Marszalek JR; Burke JP; Mandal P; Leonard PG; Cross JB; Mseeh F; Jiang Y; Chang EQ; Suzuki E; Kovacs JJ; Feng N; Gera S; Harris AL; Liu Z; Mullinax RA; Pang J; Parker CA; Spencer ND; Yu SS; Wu Q; Tremblay MR; Mikule K; Wilcoxen K; Heffernan TP; Draetta GF; Jones P
J Med Chem; 2020 Sep; 63(17):9888-9911. PubMed ID: 32787110
[TBL] [Abstract][Full Text] [Related]
9. Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages.
Zhu M; Bai L; Liu X; Peng S; Xie Y; Bai H; Yu H; Wang X; Yuan P; Ma R; Lin J; Wu L; Huang M; Li Y; Luo Y
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600555
[TBL] [Abstract][Full Text] [Related]
10. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment.
O'Brien SA; Orf J; Skrzypczynska KM; Tan H; Kim J; DeVoss J; Belmontes B; Egen JG
Cancer Immunol Immunother; 2021 Aug; 70(8):2401-2410. PubMed ID: 33511454
[TBL] [Abstract][Full Text] [Related]
11. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.
Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L
Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
13. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
[TBL] [Abstract][Full Text] [Related]
14. Efficient polymeric nanoparticles for RNAi in macrophage reveal complex effects on polarization markers upon knockdown of STAT3/STAT6.
Walther M; Jenke R; Aigner A; Ewe A
Eur J Pharm Biopharm; 2024 Apr; 197():114232. PubMed ID: 38395176
[TBL] [Abstract][Full Text] [Related]
15. CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy.
Magkouta SF; Vaitsi PC; Pappas AG; Iliopoulou M; Kosti CN; Psarra K; Kalomenidis IT
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34067348
[TBL] [Abstract][Full Text] [Related]
16. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
17. The c.1085A>G Genetic Variant of
Yeh YM; Hsu SJ; Lin PC; Hsu KF; Wu PY; Su WC; Chang JY; Shen MR
Clin Cancer Res; 2017 Oct; 23(20):6021-6030. PubMed ID: 28724665
[No Abstract] [Full Text] [Related]
18. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer.
Lv Q; Zhang Y; Gao W; Wang J; Hu Y; Yang H; Xie Y; Lv Y; Zhang H; Wu D; Hu L; Wang J
Pharmacol Res; 2024 Apr; 202():107126. PubMed ID: 38432446
[TBL] [Abstract][Full Text] [Related]
19. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy.
Figueiredo P; Lepland A; Scodeller P; Fontana F; Torrieri G; Tiboni M; Shahbazi MA; Casettari L; Kostiainen MA; Hirvonen J; Teesalu T; Santos HA
Acta Biomater; 2021 Oct; 133():231-243. PubMed ID: 33011297
[TBL] [Abstract][Full Text] [Related]
20. Phosphoinositide 3-kinase/Akt and its related signaling pathways in the regulation of tumor-associated macrophages polarization.
Yang D; Yang L; Cai J; Li H; Xing Z; Hou Y
Mol Cell Biochem; 2022 Oct; 477(10):2469-2480. PubMed ID: 35590082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]